Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2017

View Archived Issues

AVEO Oncology reports clinical, regulatory progress with tivozanib

Cellceutix initiates main clinical site for phase IIa trial of Kevetrin

Hybrigenics presents preliminary results of phase II trial of inecalcitol in patients with CML

Phase I/II results for VM-202 in subjects with amyotrophic lateral sclerosis

Seattle Genetics and Immunomedics enter global license agreement for sacituzumab govitecan

Two-year data for trans-sodium crocetinate plus temozolomide and RT in glioblastoma multiforme

Merck Sharp & Dohme begins phase I testing of MK-1454 in advanced solid tumors, lymphomas

New autism research center established at MIT

Reckitt Benckiser to acquire Mead Johnson Nutrition

Alexo initiates phase I testing of ALX-148

Hutchison MediPharma initiates first-in-human study of HMPL-453

Cancer Research UK announces the first recipients of its global Grand Challenge competition

MMJ PhytoTech announces phase II study of PTL-101 to treat refractory epilepsy in children

TP53 gene mutations linked to lower survival after stem cell transplant for myelodysplastic syndrome

Novartis files for Japanese approval of Tasigna in pediatric CML

Acacia reports results from final pivotal trial of Baremsis for rescue treatment of PONV

STADA Arzneimittel confirms expressions of interest in company

Furaprevir phase II study completed successfully in Taiwan

GlaxoSmithKline reflects on highlights of fourth quarter 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...